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Background: Bullous pemphigoid (BP) is an autoimmune 
subepidermal blistering disease characterized by tis-
sue-bound and circulating autoantibodies directed against 
BP180 and/or BP230 antigens. Various inflammatory cells 
are involved in the development of blister in BP. Objective: 
The aim of this study was to evaluate the correlation between 
peripheral leukocyte counts and BP severity. Methods: We 
retrospectively included 60 patients with BP, who had not 
been treated with systemic steroid at the time of blood 
sampling. The patients were classified into two groups, those 
with admission history (admission group) and those without 
admission history (non-admission group). Disease severity 
was evaluated using three parameters: admission history, ini-
tial steroid dosage, and modified version of a pemphigus 
scoring system. We evaluated the correlation between pe-
ripheral leukocyte counts and disease severity measured by 
the three parameters. Results: The admission group showed 
a significant increase in disease severity measured by initial 
steroid dosage and severity score compared with the non-ad-
mission group. Additionally, the admission group had in-
creased total leukocyte, eosinophil, and neutrophil counts. 
In the correlation study, the peripheral eosinophil and neu-
trophil counts showed positive correlation with BP severity 
evaluated by both initial steroid dosage and the pemphigus 
scoring system. Conclusion: Peripheral eosinophil and neu-
trophil counts can be used as a marker in predicting disease 
severity in patients with BP. (Ann Dermatol 30(5) 544∼549, 
2018)
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INTRODUCTION
Bullous pemphigoid (BP) is the most common auto-
immune subepidermal blistering disease affecting the 
elderly. BP is characterized by tissue-bound and circulat-
ing autoantibodies directed against the structural compo-
nents of hemidesmosomes, BP180 and BP230, in the der-
moepidermal junction1. According to an international 
guideline, corticosteroid is the first-line treatment for BP2. 
Since BP is a chronic disease frequently affecting elderly 
persons, long-term immunosuppressive treatment is one of 
the major causes of disease-related morbidity and mortality. 
To avoid inadequate immunosuppressive treatment, the 
precise prediction factors that correlate with disease se-
verity could be useful in clinical decision making3.
The classic form of BP is characterized by tense large blis-
ters and pruritic urticarial patches. Previous studies dem-
onstrated that wide spectra of inflammatory cells and cyto-
kines were involved in the pathogenesis of BP4 and a sig-
nificant increase in peripheral eosinophil has been re-
ported in patients with BP compared with healthy con-
trols5. Herein, we evaluated the correlation between pe-
ripheral leukocyte count and severity of BP in the patients, 
measured by admission history, initial steroid dosage, and 
disease activity score.
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Table 1. Modified version of pemphigus scoring system used to
evaluate disease activity score of BP
Extent of disease (0∼7) Intensity of therapy (1∼6)
Number of following body 
areas where the BP skin 
lesion involved (0∼6): scalp, 
face/neck, chest/abdomen, 
back, arm, leg
MPD ＜8 mg: +1
8∼24 mg: +2
＞24 mg: +3
Dapsone, minocycline, 
nicotinamide: +1
BP lesion involved in oral 
mucosa: +1
MPD pulse therapy, IVIG: +2
BP: bullous pemphigoid, MPD: methylprednisolone, IVIG: 
intravenous immunoglobulin. Disease activity score: 1∼4 
points=mild, 5∼8 points=moderate, 9∼13 points=severe.
MATERIALS AND METHODS
Patients
Medical records of 85 patients who were first diagnosed 
with BP between January 2012 and December 2016 at the 
Department of Dermatology, Gangnam Severance Hospital, 
were reviewed. BP was diagnosed by characteristic clin-
ical findings, histological evidence of subepidermal blis-
ters with inflammatory cell infiltration, linear deposition of 
immunoglobulin G (IgG) and/or C3 along the basement 
membrane zone (BMZ) by direct immunofluorescence, 
and IgG deposition on the epidermal side of salt split skin 
by indirect immunofluorescence.
Sixty patients (34 men, 26 women; mean age 74.7±12.8, 
range 30∼94) who had not been treated with cortico-
steroid at the time of blood sampling were enrolled in this 
study. Among the 60 patients, clinical photographs of the 
whole body were available for 44 (23 men, 21 women; 
mean age 77.7±10.0, range 45∼94) and involvement of 
body surface area could be assessed. This study was ap-
proved by the Institutional Review Board of Gangnam 
Severance Hospital, Yonsei University (IRB no. 320150186).
Clinical assessment
The results of the total white blood cell (WBC) and differ-
ential leukocyte (eosinophil, neutrophil, lymphocyte, and 
monocyte) counts at the time of diagnosis were examined 
in 60 patients with BP. To evaluate disease severity, we 
examined the initial corticosteroid (methylprednisolone) 
dosage and calculated the severity scores of 44 patients 
using the modified version of the pemphigus scoring sys-
tem designed by Herbst and Bystryn (Table 1)6.
First, 60 patients were classified into two groups, one 
group with admission history (admission group) and the 
other group without admission history (non-admission 
group). Disease severity, total WBC, and differential leu-
kocyte counts were compared in the two groups. Second, 
correlation of initial steroid dosage with differential leuko-
cyte count was evaluated in 60 patients. Third, correlation 
between severity score and leukocyte count was meas-
ured in 44 patients in whom the modified version of the 
pemphigus scoring system could be assessed.
Statistical methods
Comparison of the admission and non-admission groups 
was evaluated using Mann-Whitney U-test. Correlations 
between differential leukocytes with initial steroid dosage 
and severity score were performed by Spearman correla-
tion test. All statistical analyses were performed by 
GraphPad Prism 5 program (GraphPad Software, La Jolla, 
CA, USA), and a p-value＜0.05 was considered to be 
significant.
RESULTS
Difference between the admission and non-admission 
groups
Among the 60 patients enrolled in this study, 19 had ad-
mission history (12 men, 7 women; mean age 77.1±12.2, 
range 45∼93) and 41 had no history of admission (22 
men, 19 women; mean age 73.6±13.0, range 30∼94). In 
44 patients who were assessed using the modified version 
of the pemphigus scoring system, 16 were included in the 
admission group and 28 were included in the non-admis-
sion group.
As expected, the admission group was prescribed sig-
nificantly higher doses of systemic corticosteroid than the 
non-admission group (mean±standard deviation [SD]: 
39.34±13.87 vs. 15.17±13.23, p＜0.0001) (Fig. 1A). In 
the calculated severity scores, the admission group 
showed significantly a higher severity score than the 
non-admission group (mean±SD: 9.50±1.21 vs. 5.61± 
2.01, p＜0.0001) (Fig. 1B).
In the comparison of the total WBC count and differential 
leukocyte counts, the admission group showed sig-
nificantly increased total WBC (mean±SD: 11.14±3.24 vs. 
8.48±2.56, p=0.0049), eosinophil (mean±SD: 1.61±1.80 
vs. 0.46±0.44, p=0.0123), and neutrophil counts (mean± 
SD: 7.56±2.35 vs. 5.49±2.12, p=0.0019) compared with 
the non-admission group. Lymphocyte counts were ad-
versely decreased in the admission group compared with 
that of the non-admission group (mean±SD: 1.30±0.39 
vs. 1.77±0.72, p=0.0179) (Fig. 2).
Correlation between initial steroid dosage and circulating 
leukocyte counts
In the enrolled 60 patients, the initial steroid dosage pre-
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Fig. 1. Difference in (A) initial methylprednisolone (MPD) dosage and (B) severity score calculated using the modified version of
pemphigus scoring system between the admission and non-admission groups.
Fig. 2. Difference in (A) total white blood cell (WBC), (B) eosinophil, (C) neutrophil, and (D) lymphocyte counts between the admission 
and non-admission groups.
scribed to the patients at the time of the diagnosis was ret-
rospectively reviewed. Positive correlations were found 
between total WBC (rs=0.40, p=0.0016), eosinophil 
(rs=0.49, p＜0.0001), and neutrophil (rs=0.44, p=0.004) 
counts and initial steroid dosage (Fig. 3A∼C). Lymphocyte 
(rs=−0.16, p=0.21) (Fig. 3D) and monocyte counts (rs=
−0.18, p=0.17) failed to show significant correlation 
with initial steroid dosage.
Correlation between severity score and circulating 
leukocyte counts
In 44 patients with clinical photographs, severity score 
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Fig. 3. Correlation between the peripheral (A) total WBC, (B) eosinophil, (C) neutrophil, and (D) lymphocyte counts and the initial 
steroid dosage in 60 patients with BP. WBC: white blood cell, BP: bullous pemphigoid, MPD: methylprednisolone.
was calculated with the modified version of the pemphi-
gus scoring system. Assessing the correlation between the 
total and differential leukocyte counts and the severity 
score, positive correlations was found in eosinophil 
(rs=0.40, p=0.0075) and neutrophil counts (rs=0.36, 
p=0.017) (Fig. 4B, C). Total WBC (rs=0.27, p=0.077) 
(Fig. 4A), lymphocyte (rs=−0.20, p=0.20) (Fig. 4D), and 
monocyte counts (rs=−0.14, p=0.35) failed to show sig-
nificantly correlation with the severity assessed in this 
study.
DISCUSSION
The pathomechanism of blister formation in BP may be 
summarized in four steps: complement activation, recruit-
ment of inflammatory cells, release of proteolytic en-
zymes, and direct interference with the adhesive proteins 
in BMZ7. Consistent with pathogenesis of BP, lesional skin 
of BP shows subepidermal blisters with inflammatory in-
filtration consisting of lymphocytes, histiocytes, neu-
trophils, and eosinophils. In the mouse model of BP, neu-
trophils line up along the BMZ and release proteolytic en-
zymes such as neutrophil elastase, cathepsine G, collage-
nase, and matrix metalloproteinases, leading to the break-
down of dermal-epidermal cohesion8. Eosinophils are 
found in BP skin lesions and produce matrix metal-
loproteinases, elastase, and gelatinase, contributing to tis-
sue damage7.
Urticarial lesions of BP show eosinophil-dominated le-
sions similar to arthropod bite reaction, parasitic in-
festation, and hypereosinophilic syndrome9. Interestingly, 
in addition to lesional skin, approximately 50% of patients 
with BP have blood eosinophilia10, and peripheral eosino-
phil counts are reported to positively correlate with BP180 
enzyme-linked immunosorbent assay (ELISA) scores11, 
supporting the significance of these cells in BP patho-
genesis5. Recently, elevated number of eosinophils in the 
serum of patients with BP was shown to be correlated 
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Fig. 4. Correlation between the peripheral (A) total WBC, (B) eosinophil, (C) neutrophil, and (D) lymphocyte count and the severity 
scores in 44 patients with BP. WBC: white blood cell, BP: bullous pemphigoid.
with interleukin 31 serum levels, which mediates pruritus 
and promotes inflammation12. Although neutrophil is not 
a dominant feature in BP pathology, purified IgG from pa-
tients with BP is able to recruit neutrophils to the BMZ 
and induce subepidermal separation in ex vivo study, 
speculating the role of neutrophils in blister formation13.
There are several cytokines and molecules reported in as-
sociation with BP activity and severity. Increased serum 
levels of interleukin (IL)-4, IL-5, and CD30 were shown in 
BP patients, and IL-5 concentration in the blister fluid cor-
related with disease severity14. IL-5-preactivated eosino-
phils release mediators involved in blister formation15 and 
elevation in eosinophil granule proteins, such as eosino-
phil cationic protein (ECP), have been shown in the sera 
of patients with active BP16. Serum ECP level is a marker 
of eosinophil activation and shows positive correlation 
with peripheral eosinophil counts in various skin dis-
eases17. In a recent report, serum concentration of ECP 
demonstrated clinical relevance with disease severity and 
outcomes in BP patients, highlighting importance of eosi-
nophil activation in BP pathogenesis16. 
In this report, we aimed to find the correlation between 
various leukocytes and BP severity evaluated by initial ste-
roid dosage and disease activity score. Severity evaluated 
by initial steroid dosage and disease activity score showed 
significant positive correlation with peripheral eosinophil 
and neutrophil counts. Lymphocyte count failed to show 
any correlation with disease severity and expected to have 
less significance in pathogenesis of blister formation in BP. 
Such results showed that the number of neutrophils and 
eosinophils in the peripheral blood can be used as a mark-
er for predicting disease activity in initial workup and dur-
ing treatment.
In conclusion, this study shows that circulating eosinophil 
and neutrophil counts, acquirable from simple and inex-
pensive laboratory study, correlate with baseline BP se-
verity and could be helpful in estimating pre-treatment se-
verity and deciding initial steroid dosage. This is the first 
study to show correlations of various leukocytes with BP 
severity using severity scoring system. To improve our un-
Correlation Between Leukocyte Count and BP Severity
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derstanding of the role of circulating leukocytes in patients 
with BP, further study evaluating the correlation between 
differential leukocyte counts and disease severity during 
the treatment is needed.
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